COVID-19 Community
Published October 19, 2020 | Version v1.0.0
Other Article Open

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

Creators

  • 1. ROR icon Brown University
  • 2. Argos Laboratory
  • 3. ROR icon Northwestern University
  • 4. ROR icon University of California, San Francisco

Other

original_citation: De Souza A, Tavora FA, Mahalingam D, Munster PN, Safran HP, El-Deiry WS, Carneiro BA. Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response. Frontiers in Immunology. 2020;11:3.

Files

fimmu-11-595289.pdf

Files (127.3 kB)

Name Size Download all
md5:ad0c89c2fc635e5dad597b9096d6cb2d
127.3 kB Preview Download

Additional details

Identifiers

PMID
33193448

Related works

Is related to
https://www.frontiersin.org/articles/10.3389/fimmu.2020.595289/full (URL)

Dates

Created
2020-10-19
When the item was originally created.